THIS MEDIA RELEASE IS NOT FOR DISTRIBUTION TO THE UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Paladin Labs Inc. (PLB.TO) ("Paladin") today announced that it has reached a ...

DUBLIN, July 15, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into agreements with Quoin Pharmaceuticals Inc.

View post: 25-year-old women’s fashion chain closes stores, no bankruptcy Terms of the deal call for Malvern, Pa.-based Endo to pay C$77 for each Paladin share, a premium of 20% to the target’s $63.91 ...

MONTREAL, Jan. 22, 2024 /PRNewswire/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI ® (cenobamate tablets) is now available in Canada. XCOPRI is ...

Two years ago, Endo Pharmaceuticals began to transform itself into an innovation-driven drug company. The Pennsylvania-based firm, which until then was mostly a supplier of branded and generic ...

MALVERN, Pa. (AP) -- Endo Health will spend about $1.5 billion to buy the Canadian specialty drug maker Paladin Labs, and both will then be folded into a newly-formed Irish holding company. Endo also ...

(Reuters) - Endo International Plc has discussed a sale of Paladin Labs Inc, its Montreal-based specialty pharmaceutical subsidiary, to Canadian drug maker Knight Therapeutics Inc , people familiar ...

The product is under investigation for the treatment of Netherton syndrome, a rare disease DUBLIN, July 15, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its ...